08:00 , Nov 12, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MicroRNA-10b (miR-10b)

Cancer In vitro and mouse studies suggest an miR-10b inhibitor plus doxorubicin could help treat metastatic breast cancer. Levels of miR-10b were higher in human metastatic breast cancer cell lines and in primary tumors from...
07:00 , Aug 20, 2012 |  BioCentury  |  Finance

Ducks in a row

Ducks in a row microRNA play Regulus Therapeutics Inc. is hoping Verastem Inc. (NASDAQ:VSTM) didn't satiate investor appetite for preclinical biotech plays. Last week, Regulus filed to raise up to $57.5 million in an IPO,...
07:00 , Apr 8, 2010 |  BC Innovations  |  Targets & Mechanisms

miRNA inhibition of metastasis

A U.S. team that included researchers from Regulus Therapeutics Inc. has reported the first successful inhibition of a microRNA- ^ miR-10b-in tumor cells, a feat that previously had only been accomplished in normal tissue. 1...
07:00 , Apr 5, 2010 |  BC Week In Review  |  Clinical News

Regulus preclinical data

In a mouse model of breast cancer, antagomir-10b significantly reduced the number of macroscopically visible pulmonary breast cancer metastases by 86% compared with saline-treated controls (p=0.00005). The antisense oligonucleotide targeting microRNA-10b also significantly reduced the...
07:00 , Apr 1, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer MicroRNA-10b (miR-10b) In vitro and mouse studies suggest that antagonizing miR-10b could help prevent breast cancer metastasis. In mice, an anti-miRNA oligonucleotide (antagomir)...